We aim to revolutionize the injectable drug delivery market with the best solutions for patient use and outcomes. Our market entry will be the world's smallest, most easily used and problem-free insulin pump. Entry will precede applications to enormous drug markets in GLP-1s and monoclonal antibodies. We will enter the insulin pump market with a white-label product developed for a current manufacturer, with 1B sales by 2030.